Identification Of Toxicity Mechanisms Through The Relationship Between Chemical Exposure And Changes In Genome - Wide Gene Expression Pattern By Using Bioinformatics Tools And Databases | 4758
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Identification of toxicity mechanisms through the relationship between chemical exposure and changes in genome - Wide gene expression pattern by using bioinformatics tools and databases

3rd World Congress on Biotechnology

G. Rajeshwari, R. Sangeetha and M. Subash Chandra Bose

Posters: Agrotechnol

DOI: 10.4172/2155-952X.S1.020

Toxicogenomics is a form of analysis by which the activity of a particular toxin or chemical substance on living tissue can be identified based upon a profiling of its known effects on genetic material. Once viable, the technique should serve for toxicology and toxin-determination, a role analogous to DNA-testing in forensic identification of individuals. Toxicogenomics may also be of use as a preventative measure to predict adverse "side", i.e. toxic effects, of pharmaceutical drugs on susceptible individuals. This involves using genomic techniques such as gene-expression level profiling and single nucleotide polymorphism analysis of genetic variation of individuals. Studies of those types are then correlated to adverse toxicological effects in clinical trials so that suitable diagnostic markers (measurable signs) for these adverse effects can be developed. Using such methods, it would then be possible theoretically to test an individual patient for his or her susceptibility to these adverse effects before administering a drug. Patients who would show the marker for an adverse effect would be switched to a different drug. While this approach is currently theoretical, it has great potential. There are many well publicized cases in which popular drugs such as Vioxx and Fen-Phen were pulled from the market because of toxic effects experienced by a small percentage of patients, with a cost of many billions of dollars to the companies responsible, and the loss of a helpful drug to individuals not at risk for the side effects. If an accurate test using Toxicogenomic methods could be developed, that successfully identified patients who are susceptible to these adverse effects. These drugs could be returned to market with very little risk. Such would have the triple benefit of re-allowing the therapeutic use of a previously banned drug, preventing potentially life-threatening side effects, and restoring the majority of the lost market share of these drugs to the company that developed them. Predicting its immense scope of application, we hence put forth this theory as a small donation to the sea named biotechnology.
G. Rajeshwari is pursuing her undergraduate in Bachelor of Biotechnology (IVth year) at Rajalakshmi Engineering College affliated to Anna University, Chennai, India. She performed many Paper and Poster Presentations in several National Conferences. She have underwent training in Bioinformatics tools, learnt several techniques related to molecular biology field, Chromatography Techniques (Protein Purification Techniques) and Animal Handling. She had a chance of understanding the techniques & methodologies followed in Pharmaceutical industries. She did piece of work on toxicogenomics & Stem Cells of her guide, M. Subash Chandra Bose.